Evidence map›Paper›PMID 42718444›Full record

ArticleFrontiers in oncology2026

Deep learning-radiomics-SUVmax integration from

Yun Zhang, Ying Cao, Shanshan Xu, Yan Tang, Jian He, Jing Chen, Ziwei Nie, Yuxiao Hu

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yun Zhang *Department of PET/CT Center, Jiangsu Cancer Hospital& Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Ying Cao *School of Mathematics, Nanjing University, Nanjing, China.
Shanshan XuDepartment of PET/CT Center, Jiangsu Cancer Hospital& Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Yan TangDepartment of PET/CT Center, Jiangsu Cancer Hospital& Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Jian HeDepartment of Nuclear Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Jing ChenDepartment of Nuclear Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Ziwei NieSchool of Mathematics, Nanjing University, Nanjing, China.
Yuxiao HuDepartment of PET/CT Center, Jiangsu Cancer Hospital& Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This study aimed to develop and evaluate deep learning (DL) models of primary tumor (T) and cervical metastatic lymph nodes (CMLNs) using fluorine-18 fluorodeoxyglucose positron emission computed tomography ( Methods: A two-center retrospective cohort of 218 patients (105 SDM, 113 non-SDM) was analyzed. Three DL architectures (ResNet18, DenseNet121, EfficientNet-B0) were trained on CT-only, PET-only, and fused CT+PET images. Nine models combining DL features, radiomic features of T + CMLNs or T-only, clinical data, and SUVmax-T using Multilayer Perceptron (MLP) and Random Forest (RF) classifiers were established. Multiple MLP benchmark models were built based on separate T/N staging, clinical data, SUVmax-T and deep features for comparative analysis. Performance was assessed via accuracy, precision, recall, F1-score, and ROC-AUC. Permutation feature importance analysis identified core predictors of the optimal RF model, and the optimal hybrid model underwent external multicenter validation. Results: Dual-modal PET/CT networks surpassed single-modality models, with ResNet18 yielding the highest internal ROC-AUC of 0.804, superior to DenseNet121 (0.791) and EfficientNet-B0 (0.779). Integrating radiomic features (T), clinical parameters and SUVmax-T continuously elevated model discrimination, and the MLP hybrid model reached the peak internal ROC-AUC of 0.839 (recall = 0.747), outperforming the RF model (ROC-AUC = 0.787, recall = 0.777). Models built only on T/N staging reached an internal AUC of 0.476 and an external AUC of 0.513, while integrating deep features boosted their predictive AUC to 0.658 (internal) and 0.688 (external). External validation of the MLP hybrid model showed an ROC-AUC of 0.701 and a PR-AUC of 0.571. SUVmax-T was identified as the most important predictive feature in the RF hybrid model. Conclusion: Integrating ResNet18 (CT+PET) features with radiomic features (T), SUVmax-T and clinical data in an MLP framework yielded the highest performance, with SUVmax-T identified as an SDM predictor. Comparative benchmark analysis verified that this multimodal hybrid model achieved better discriminative performance than models relying solely on conventional T and N staging.

Indexed as

18F-FDG PET/CTdeep learninghybrid modelnasopharyngeal carcinomasynchronous distant metastases

Identifiers

PMID42718444
PMCPMC13553355

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.